{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:38:23Z","timestamp":1794577103412,"version":"4.9.1"},"reference-count":51,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2515771","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T01:57:22Z","timestamp":1749088642000},"page":"922-933","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["A cost-effectiveness analysis of deucravacitinib\n                    <i>vs.<\/i>\n                    apremilast in\u00a0moderate-to-severe psoriasis patients in Japan"],"prefix":"10.1080","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6498-2950","authenticated-orcid":false,"given":"Gijs","family":"van de Wetering","sequence":"first","affiliation":[{"name":"Executive Director, Modelling & Meta-Analysis, OPEN Health","place":["Rotterdam, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2149-2345","authenticated-orcid":false,"given":"Hyunchung","family":"Kim","sequence":"additional","affiliation":[{"name":"Health Economics Outcomes Research (HEOR), Market Access & Government Affairs (MAx & GA), Bristol Myers Squibb","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Roberts","sequence":"additional","affiliation":[{"name":"Global Health Economics and Outcomes Research, Bristol Myers Squibb","place":["Uxbridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-6821","authenticated-orcid":false,"given":"Yusuke","family":"Hikichi","sequence":"additional","affiliation":[{"name":"Health Economics Outcomes Research (HEOR), Market Access & Government Affairs (MAx & GA), Bristol Myers Squibb","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Smith","sequence":"additional","affiliation":[{"name":"Associate Market Access Consultant-SMA, OPEN Health","place":["York, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-135X","authenticated-orcid":false,"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Teikyo University","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"WHO. Global report on psoriasis 2016 [cited 2023 April 5]. https:\/\/www.who.int\/publications\/i\/item\/9789241565189"},{"key":"e_1_3_5_3_1","unstructured":"NICE. Psoriasis: assessment and management; 2012 [cited 2023 April 5]. https:\/\/www.nice.org.uk\/guidance\/cg153\/resources\/psoriasis-assessment-and-management-pdf-35109629621701"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-015-0539-8"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033217"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"issue":"5","key":"e_1_3_5_8_1","first-page":"S2","article-title":"Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine","volume":"33","author":"Alwan W","year":"2015","unstructured":"Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol. 2015;33(5 Suppl):S2\u2013S6.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_5_9_1","volume-title":"Pharmacotherapy: a pathophysiologic approach: psoriasis","author":"DiPiro JT","year":"2020","unstructured":"DiPiro JT, Posey LM, Haines ST, Nolin TD, Ellingrod V. Pharmacotherapy: a pathophysiologic approach: psoriasis. New York, NY: McGraw-Hill Education; 2020."},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.08.005"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-01906-z"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1044492"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.82"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01064-1"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2022.4245"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16691"},{"key":"e_1_3_5_18_1","unstructured":"Saeki H Mabuchi T Akihiko A et\u00a0al. Japanese dermatological association guidance: Guidance for the use of oral Janus kinase (JAK) inhibitors (JAK1 inhibitors and TYK2 inhibitors) in psoriasis; 2023 [cited 2024 Oct 16]. https:\/\/www.dermatol.or.jp\/uploads\/uploads\/files\/guideline\/hif01-04_guidance.pdf."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00986-0"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16543"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17074"},{"key":"e_1_3_5_22_1","unstructured":"EMA. Summary of product characteristics: Sotyktu; 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sotyktu-epar-product-information_en.pdf."},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_3_5_25_1","unstructured":"BMS. Pooled analysis of POETYK-PSO-1 and POETYK-PSO-2; 2021."},{"key":"e_1_3_5_26_1","volume-title":"European Academy of Dermatology & Venereology Symposium, St Julians, Malta","author":"Armstrong A","year":"2024","unstructured":"Armstrong A, Lebwohl M, Warren RB, et\u00a0al. Deucravacitinib in plaque psoriasis: 4-year safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2, and LTE trials. In: European Academy of Dermatology & Venereology Symposium, St Julians, Malta; 2024."},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16740"},{"key":"e_1_3_5_28_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health. New C2H report: Deucravacitinib (Sotyktu); 2024. https:\/\/c2h.niph.go.jp\/en\/info\/news\/20240428\/."},{"key":"e_1_3_5_29_1","unstructured":"NICE. Bimekizumab for treating moderate to severe plaque psoriasis [TA723]; 2021. https:\/\/www.nice.org.uk\/guidance\/ta723."},{"key":"e_1_3_5_30_1","unstructured":"NICE. Apremilast for treating moderate to severe psoriasis [TA419]; 2016. https:\/\/www.nice.org.uk\/guidance\/ta419."},{"key":"e_1_3_5_31_1","unstructured":"NICE. Secukinumab for treating moderate to severe plaque psoriasis [TA350]; 2015. https:\/\/www.nice.org.uk\/guidance\/ta350."},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_420_23"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1532905"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1744505"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01034-7"},{"key":"e_1_3_5_36_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health. Preparing cost-effectiveness evaluation to the central social insurance medical council; 2022. https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf"},{"key":"e_1_3_5_37_1","unstructured":"Xe.com. International money transfers and global currency conversions; 2025 [cited 2025 May 21]; https:\/\/www.xe.com\/"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.673"},{"key":"e_1_3_5_39_1","unstructured":"NICE. Brodalumab for treating moderate to severe plaque psoriasis [TA511]; 2018. https:\/\/www.nice.org.uk\/guidance\/ta511"},{"key":"e_1_3_5_40_1","unstructured":"NICE. Deucravacitinib for treating moderate to severe plaque psoriasis; 2023 [cited 2024 June 14]. https:\/\/www.nice.org.uk\/guidance\/ta907\/resources\/deucravacitinib-for-treating-moderate-to-severe-plaque-psoriasis-pdf-82615431710149."},{"key":"e_1_3_5_41_1","volume-title":"NICE DSU technical support document 12: the use of health state utility values in decision models","author":"Ara R","year":"2011","unstructured":"Ara R, Wailoo A. NICE DSU technical support document 12: the use of health state utility values in decision models. London: National Institute for Health and Care Excellence (NICE); 2011."},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0165-7"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550160053038"},{"key":"e_1_3_5_44_1","unstructured":"MHLW. Life tables; 2017. https:\/\/www.mhlw.go.jp\/english\/database\/db-hw\/vs02.html."},{"key":"e_1_3_5_45_1","unstructured":"Pharmaceuticals and Medical Devices Agency. Price adjustment based on the results of the cost-effectiveness evaluation of Sotyktu. 2024 [cited 2024 October]. https:\/\/www.mhlw.go.jp\/content\/12404000\/001254178.pdf"},{"key":"e_1_3_5_46_1","unstructured":"MFLW. Medical fee schedule; 2023. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000188411_00037.html."},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15803"},{"key":"e_1_3_5_48_1","unstructured":"6NCNDB. Research project for the establishment of an NDB research system for health policy and other purposes through 6NC collaboration; 2024 [cited 2024 11 June]; Available from: https:\/\/ndb6nc.ncgm.go.jp\/eng\/outline\/index.html."},{"key":"e_1_3_5_49_1","unstructured":"Medical Data Vision Co. Ltd. Japanese MDV database; 2024. https:\/\/en.mdv.co.jp"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14213"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16566"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00747-5"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2515771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:44:17Z","timestamp":1766400257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2515771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2515771"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2515771","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}